Cardinal Health has agreed to pay $26.8 million to settle charges it illegally monopolized markets in 25 cities for the sale of low-energy radiopharmaceuticals to hospitals and clinics, the Federal Trade Commission said on Monday.
The FTC accused Cardinal, which became the biggest U.S. operator of radiopharmacies through acquisitions in 2003 and 2004, of pressuring companies that make radiopharmaceuticals used in heart stress tests to refuse to sell to Cardinal’s rivals in the 25 U.S. cities.
Full Content: The New York Times
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Federal Reserve Greenlights Capital One’s $35.3 Billion Acquisition of Discover
Apr 18, 2025 by
CPI
Google to Appeal Partial Ruling in DOJ Antitrust Case
Apr 18, 2025 by
CPI
Indian Ad Agencies Warned Against WhatsApp Discussions After Antitrust Raids
Apr 17, 2025 by
CPI
US Court Ruling Against Google Spurs Fresh Antitrust Tensions in Europe
Apr 17, 2025 by
CPI
AstraZeneca Accused of Stifling Biosimilar Competition for Rare Disease Drug
Apr 17, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – The Airline Industry
Apr 10, 2025 by
CPI
Boosting Competition in International Aviation
Apr 10, 2025 by
Jeffrey N. Shane
Reshaping Competition Policy for the U.S. Airline Industry
Apr 10, 2025 by
Diana L. Moss
Algorithmic Collusion in the Skies: The Role of AI in Shaping Airline Competition
Apr 10, 2025 by
Qi Ge, Myongjin Kim & Nicholas Rupp
Competition in U.S. Airline Markets: Major Developments and Economic Insights
Apr 10, 2025 by
Germán Bet